(Q37650394)

21 August 2017

1 reference

title

The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus (English)

1 reference

21 August 2017

1 reference

1 reference

1

Ivan Gentile

1 reference

21 August 2017

Maria Aurora Carleo

2

1 reference

21 August 2017

Federico Borgia

series ordinal

3

1 reference

21 August 2017

Giuseppe Castaldo

series ordinal

4

1 reference

21 August 2017

Guglielmo Borgia

series ordinal

5

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

1 reference

21 August 2017

19

1 reference

21 August 2017

1

1 reference

21 August 2017

151-159

1 reference

New therapeutic opportunities for hepatitis C based on small RNA.

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

The natural history of hepatitis C virus (HCV) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Epidemiology of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Myasthenia gravis during low-dose IFN-alpha therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Specifically targeted antiviral therapy for hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Genetic diversity and evolution of hepatitis C virus--15 years on

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Characterization of resistance mutations against HCV ketoamide protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

A systematic review of the associations between dose regimens and medication compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

A step forward in therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

Pro-hepcidin is unable to degrade the iron exporter ferroportin unless maturated by a furin-dependent process

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903501505

10.1517/13543780903501505

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference